ApoA1 has anti-atherogenic effects, and some APOA1 polymorphisms are associated with MetS: the G-75A with hypertension and C+83T with obesity and with higher levels of glycated hemoglobin [123,132]. Here, APOA1 is linked to metabolic syndrome.